Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

In a recent study posted to the bioRxiv* pre-print server, researchers from Belgium evaluated the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drugs in a severe combined immunodeficient (SCID) mouse model.
In a recent study posted to the bioRxiv* pre-print server, researchers from Belgium evaluated the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drugs in a severe combined immunodeficient (SCID) mouse model.